Nicolas J. Schlienz, Ph.D.
Affiliations: | 2015- | Psychiatry and Behavioral Sciences | Johns Hopkins University School of Medicine, Baltimore, MD, United States |
Area:
Cannabis, Tobacco, Withdrawal, Reward Processing, CognitionGoogle:
"Nicolas J. Schlienz"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Rebecca J. Houston | research assistant | 2005-2009 | Research Institute on Addictions - University at Buffalo |
| Larry W. Hawk | grad student | 2008-2015 | SUNY Buffalo |
| Ryan Vandrey | post-doc | 2015- | Johns Hopkins Medical School (PsychTree) |
Collaborators
Sign in to add collaborator| Robert C. Schlauch | collaborator | 2014- | University of South Florida |
| Dustin C. Lee | collaborator | 2016- | Johns Hopkins Medical School |
| Denis G. Antoine | collaborator | 2017- | Johns Hopkins Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Goulette M, Schlienz NJ, Case AA, et al. (2024) Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 32: 210 |
| Lee DC, Schlienz NJ, Herrman ES, et al. (2023) Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder. Journal of Substance Use and Addiction Treatment. 209180 |
| Garcia-Romeu A, Elmore J, Mayhugh RE, et al. (2022) Online survey of medicinal cannabis users: Qualitative analysis of patient-level data. Frontiers in Pharmacology. 13: 965535 |
| Martin EL, Strickland JC, Schlienz NJ, et al. (2021) Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Frontiers in Psychiatry. 12: 729800 |
| Strickland JC, Jackson H, Schlienz NJ, et al. (2021) Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. Epilepsy & Behavior : E&B. 122: 108205 |
| Mahoney MC, Park E, Schlienz NJ, et al. (2021) Transitioning to remote clinic visits in a smoking cessation trial during the SARS coronavirus-2 pandemic: Mixed methods evaluation. Jmir Formative Research |
| Schlienz NJ, Scalsky R, Martin EL, et al. (2020) A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health. Cannabis and Cannabinoid Research |
| Mahoney MC, Ashare R, Schlienz N, et al. (2020) Making lemonade from SARS coronavirus-2 lemons: Transitioning a smoking cessation trial to a virtual platform. Journal of Substance Abuse Treatment. 117: 108100 |
| Schlienz NJ, Spindle TR, Cone EJ, et al. (2020) Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug and Alcohol Dependence. 211: 107969 |
| Spindle TR, Cone EJ, Schlienz NJ, et al. (2019) Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users. Journal of Analytical Toxicology |